Measuring diagnostic performance of COVID-19 tests: lessons for the next pandemic

References

1. Huggett JF, Moran-Gilad J, Lee JE. COVID-19 new diagnostics development: novel detection methods for SARS-CoV-2 infection and considerations for their translation to routine use. Curr Opin Pulm Med. 2021;27(3):155-62.  https://doi.org/10.1097/MCP.0000000000000768  PMID: 33654014 
2. Puyskens A, Krause E, Michel J, Nübling CM, Scheiblauer H, Bourquain D, et al. Establishment of a specimen panel for the decentralised technical evaluation of the sensitivity of 31 rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021. Euro Surveill. 2021;26(44):2100442.  https://doi.org/10.2807/1560-7917.ES.2021.26.44.2100442  PMID: 34738516 
3. Scheiblauer H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C, et al. Comparative sensitivity evaluation for 122 CE-marked rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021. Euro Surveill. 2021;26(44):2100441.  https://doi.org/10.2807/1560-7917.ES.2021.26.44.2100441  PMID: 34738515 
4. Walle I, Leitmeyer K, Broberg EK. the European COVID-19 microbiological laboratories group. Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020. Euro Surveill. 2021;26(45):2001675.
5. Evans D, Cowen S, Kammel M, O’Sullivan DM, Stewart G, Grunert HP, et al. The dangers of using Cq to quantify nucleic acid in biological samples; a lesson from COVID-19. Clin Chem. 2021;hvab219.  https://doi.org/10.1093/clinchem/hvab219  PMID: 34633030